IQVIA (IQV) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of IQVIA (NYSE: IQV) recently:

• 12/20/2024 – IQVIA is now covered by analysts at Stephens. They set an “overweight” rating and a $250.00 price target on the stock.
• 12/13/2024 – IQVIA had its price target lowered by analysts at Bank of America Co. from $255.00 to $235.00. They now have a “buy” rating on the stock.
• 12/12/2024 – IQVIA had its price target lowered by analysts at Truist Financial Co. from $265.00 to $261.00. They now have a “buy” rating on the stock.
• 12/11/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $270.00 price target on the stock.
• 12/11/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at William Blair.
• 12/11/2024 – IQVIA had its price target lowered by analysts at Robert W. Baird from $213.00 to $212.00. They now have a “neutral” rating on the stock.
• 12/4/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $270.00 price target on the stock.
• 11/28/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/20/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/19/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $248.00 price target on the stock, down previously from $260.00.
• 11/8/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/5/2024 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $279.00 to $240.00. They now have an “overweight” rating on the stock.
• 11/4/2024 – IQVIA had its price target lowered by analysts at Morgan Stanley from $280.00 to $265.00. They now have an “overweight” rating on the stock.
• 11/4/2024 – IQVIA had its price target lowered by analysts at Truist Financial Co. from $286.00 to $265.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Barclays PLC from $260.00 to $255.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $270.00 price target on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Robert W. Baird from $256.00 to $223.00. They now have a “neutral” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at BTIG Research from $290.00 to $260.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $270.00 to $265.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at TD Cowen from $270.00 to $255.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $280.00 to $250.00. They now have a “buy” rating on the stock.
• 10/30/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

IQVIA Trading Up 0.4 %

Shares of IQV opened at $199.99 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business has a 50-day moving average of $208.22 and a 200 day moving average of $223.20. The firm has a market cap of $36.30 billion, a P/E ratio of 26.25, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Trading of IQVIA

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. lifted its stake in IQVIA by 6.8% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,119 shares of the medical research company’s stock worth $4,888,000 after purchasing an additional 1,478 shares in the last quarter. Simmons Bank bought a new stake in IQVIA during the second quarter valued at $203,000. HB Wealth Management LLC grew its position in IQVIA by 66.2% during the second quarter. HB Wealth Management LLC now owns 3,971 shares of the medical research company’s stock worth $840,000 after buying an additional 1,582 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in IQVIA by 4.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 74,825 shares of the medical research company’s stock worth $15,821,000 after acquiring an additional 3,015 shares during the last quarter. Finally, Smith Salley Wealth Management raised its holdings in shares of IQVIA by 12.0% in the 2nd quarter. Smith Salley Wealth Management now owns 10,016 shares of the medical research company’s stock valued at $2,118,000 after acquiring an additional 1,071 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.